[[{“value”:”
Zealand Pharma A/S plans to establish a new research hub in Cambridge at Healthpeak Properties’ 35 CambridgePark Drive, positioning the site as the biotechnology company’s primary U.S. address. The facility is expected to open in September, adding a dedicated U.S. research presence to the firm’s existing operations.
The company, which focuses on metabolic health, described the Cambridge hub as an important addition to its research footprint. Leadership framed the move as complementary to the research activity already underway in Denmark, tying the new site to Zealand Pharma’s broader ambition to strengthen its position in obesity and metabolic health.
The planned hub will house research laboratories alongside office space, giving the company a combined environment for scientific work and corporate functions. In addition to lab and office areas, the layout will incorporate meeting rooms and collaborative spaces intended to accommodate colleagues from across the organization as they work together on U.S.-based initiatives.
As part of this expansion, Zealand Pharma is actively recruiting staff for the Cambridge facility. The new hub will be located within a three-building campus totaling 449,000 square feet, providing the company with access to a larger research-oriented environment while it grows its presence in the U.S. market.
The decision to base the U.S. hub at 35 CambridgePark Drive links Zealand Pharma with an established life science setting. While specific lease, ownership, or financial details were not disclosed, the announcement signals a long-term operational commitment to Cambridge and a continued build-out of the company’s global research network.
The post Zealand Pharma to Open U.S. Research Hub at Healthpeak’s 35 CambridgePark Drive in September appeared first on CRE Market Beat.
“}]]
